辰欣藥業(603367.SH):子公司辰欣佛都藥業擬進行股改並更名
格隆匯10月21日丨辰欣藥業(603367.SH)公佈,公司於2022年10月21日召開第四屆董事會第十六次會議審議通過了《關於公司控股子公司進行股份制改造及更名的議案》。
辰欣佛都藥業(汶上)有限公司擬整體變更發起設立股份有限公司,名稱變更為:山東辰欣佛都藥業股份有限公司(最終以市場監督管理部門登記的為準)。公司將聘請資產評估機構對辰欣佛都藥業(汶上)有限公司審計後的資產及負債進行整體評估,並聘請會計師事務所出具專項審計報吿及確定股份公司實收股本。整體變更後設立的股份有限公司將設立股東大會、董事會和監事會,主營業務不變,經營期限為長期存續。
辰欣佛都藥業(汶上)有限公司是公司合併報表範圍內的控股子公司,該次股改不涉及公司放棄相關股東權利或增加股東義務,上市公司合併報表範圍未發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.